Document Detail

Recombinant human growth hormone treatment in elderly patients undergoing elective total hip replacement.
MedLine Citation:
PMID:  12519419     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Measures to prevent postoperative catabolism may be of greatest benefit in the elderly because of their reduced lean tissue reserve. We examined the effects of recombinant human growth hormone (GH) treatment on body composition and physical performance in elderly patients undergoing elective total hip replacement. METHODS: We recruited 33 patients (aged 60-82 years) scheduled for hip replacement. The study was double-blind and placebo-controlled with parallel groups. GH or placebo was administered for 14 weeks preoperatively (target GH dose 0.04 U/kg/day) and 4 weeks postoperatively (with dose doubled for first 2 weeks postoperatively). Serum IGF-I, body composition, mid-thigh muscle cross-sectional area, muscle strength and 4-min walking distance were measured at baseline, 2-3 days preoperatively and 4 weeks postoperatively. RESULTS: Mean serum IGF-I doubled during GH treatment. Lean body mass increased preoperatively by an average of 5.2% (representing 1.8 kg) with GH treatment (P < 0.05 vs. placebo), but fell postoperatively by 3% in both groups. Similar changes pre- and postoperatively were seen for mid-thigh muscle cross-sectional area, such that there was no net loss in the GH group but a fall of more than 10% in the placebo group (P < 0.005 vs. GH). There was a trend towards a favourable effect of GH on strength in the majority of muscles tested, but this was significant only for the abductors of the nonoperated hip (P < 0.02), where there was a 7% increase in strength over the whole study compared with a 25% decrease in the placebo group. Four-minute walking distance improved postoperatively by a mean of 26.9 m in the GH group compared with a 19.5 m reduction in the placebo group (P < 0.05). Dose-related side-effects were seen in the majority of patients receiving GH. CONCLUSIONS: In elderly patients undergoing total hip replacement, preoperative GH treatment results in improvements in lean body mass and skeletal muscle mass that are sufficient to offset postoperative losses. The treatment may also preserve or improve muscle strength and postoperative walking ability.
Andrew J Weissberger; Anastasios D Anastasiadis; Ian Sturgess; Finbarr C Martin; Michael A Smith; Peter H Sönksen
Related Documents :
9539069 - Effects of human recombinant growth hormone (rhgh) on inflammatory responses in patient...
12942339 - Direct transnasal approach for pituitary surgery.
10865479 - The natural history of untreated vestibular schwannomas. is there a role for conservati...
10728629 - Persistent increase of prl after oral contraceptive treatment. alterations in dopaminer...
20453679 - A randomized controlled trial of growth hormone in active pediatric crohn disease.
18445999 - Case study of a 15-year-old boy with mccune-albright syndrome combined with pituitary g...
21789509 - Single-incision sleeve gastrectomy versus conventional laparoscopic sleeve gastrectomy-...
2721049 - Failed anterior acromioplasty. a review of 51 cases.
23519049 - Opiate-dependent patients on a waiting list for methadone maintenance treatment are at ...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical endocrinology     Volume:  58     ISSN:  0300-0664     ISO Abbreviation:  Clin. Endocrinol. (Oxf)     Publication Date:  2003 Jan 
Date Detail:
Created Date:  2003-01-09     Completed Date:  2003-02-25     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0346653     Medline TA:  Clin Endocrinol (Oxf)     Country:  England    
Other Details:
Languages:  eng     Pagination:  99-107     Citation Subset:  IM    
Department of Endocrinology, St Thomas' Hospital, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Arthroplasty, Replacement, Hip / rehabilitation*
Body Composition / drug effects
Double-Blind Method
Human Growth Hormone / adverse effects,  therapeutic use*
Insulin-Like Growth Factor I / metabolism
Isometric Contraction / drug effects
Middle Aged
Muscle, Skeletal / pathology
Postoperative Period
Preoperative Care / methods*
Recombinant Proteins / adverse effects,  therapeutic use
Reg. No./Substance:
0/Recombinant Proteins; 12629-01-5/Human Growth Hormone; 67763-96-6/Insulin-Like Growth Factor I

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Acetylcholine does not play a major role in mediating the endocrine responses to ghrelin, a natural ...
Next Document:  A signal peptide mutation of the arginine vasopressin gene in monozygotic twins.